ADVISORY, Nov 3, 2009 (GlobeNewswire via COMTEX News Network) --

 What:
 Auxilium Pharmaceuticals, Inc. (AUXL) will visit the NASDAQ
 MarketSite in New York City's Times Square to mark its five year
 anniversary on the NASDAQ exchange.  In honor of the occasion,
 Armando Anido, Chief Executive Officer and President of the
 Company, will preside over the NASDAQ Closing Bell.
 Where:
 NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast
 Studio
 When:
 Wednesday, November 4th 2009 at 3:45 p.m. to 4:00 p.m. ET
 Contacts:
 Will Sargent
 (484) 321-5900 (office)
 wsargent@auxilium.com
 Rebekah Sinzheimer
 (312)729.4239
 rsinzheimer@golinharris.com
 NASDAQ MarketSite:
 Robert Madden
 (646) 441-5045
 Robert.Madden@NASDAQOMX.com

Feed Information:

The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045.

Radio Feed:

An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/pages/NASDAQ-OMX/108167527653 For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaqomx

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a high-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Auxilium Pharmaceuticals, Inc. (AUXL):

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's disease, and the biologics license application is under review at the FDA for the treatment of Dupuytren's disease. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development. The Company is currently seeking a partner to further develop these product candidates. Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. Auxilium also has options to all indications using XIAFLEX for non-topical formulations. For additional information, visit http://www.auxilium.com.

 Continued...